Boston Scientific ‘Unlikely to Meet’ Earnings Guidance After Cyberattack. Stock Falls.
Boston Scientific says it is unlikely to meet earnings guidance after a cyberattack, sending BSX shares lower. The immediate setup shifts toward estimate risk and the timing of operational recovery, with the next company update more important than the initial stock reaction.
Yahoo Finance reported on September 8 that Boston Scientific is unlikely to meet its earnings guidance following a cyberattack, and that the stock fell. The report did not specify the affected systems, the duration of the disruption, the amount of guidance at risk, or whether the issue was limited to operations, billing, manufacturing, or other functions.
The warning changes the near-term earnings narrative for a company that reported $20.1B of fiscal 2025 revenue, up 19.9% year over year, with a 14.4% net margin and $1.94 diluted EPS. Those annual figures establish the scale of the business but do not quantify the cyberattack’s effect on the current reporting period.
For BSX, the concrete transmission mechanism is earnings guidance: any disruption to production, shipments, procedures, order processing, or administrative systems could affect revenue recognition or costs before the company restores normal operations. The headline does not identify outside vendors, regulators, customers, or a specific business line affected.
The evidence is incomplete. Yahoo Finance did not report a dollar impact, revised guidance range, incident timeline, or management commentary beyond the statement that guidance is unlikely to be met, so the severity and persistence of the earnings hit remain unresolved.
The next decisive information is Boston Scientific’s formal update on the incident and its next earnings or guidance disclosure. Investors will need the revised outlook, the affected quarter, any recovery timetable, and evidence that the company’s underlying growth trajectory remains intact after the disruption.
The cyberattack moves the earnings-risk balance to the downside for BSX, with the size and duration of the guidance miss still unquantified.
The immediate risk is to BSX’s earnings visibility: management’s warning establishes a downside to guidance, but the report gives no quantified impact or recovery timetable. The strong 19.9% revenue growth in fiscal 2025 is a useful operating backdrop, yet it does not offset the lack of current-period detail needed to size the disruption or support a dated directional call.
The trade read fails if Boston Scientific quickly restores affected operations and confirms only a minimal or temporary earnings impact.
CoverageSource: Yahoo Finance · Published here TUE, SEP 8 · 7:06 AM ET · 3 reports · 3 publishers in this record · latest listed: Yahoo Finance · TUE, SEP 8 · 10:22 AM ETHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
BSX’s fiscal 2025 revenue grew 19.9% to $20.1B, leaving a substantial underlying growth record if the cyberattack proves contained and guidance is largely preserved.
The guidance warning is already explicit, while Yahoo Finance did not disclose the affected systems, financial impact, or recovery timeline, leaving the downside risk materially unresolved.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →